Medische Oncologie Nummer 3, pp. 36-37
mei 2019, jaargang 22
Medische Oncologie Nr. 3, pp. 36-37
mei 2019, jr. 22
Beleid

OFFLABEL-INDICATIES BIJ BLAASCARCINOOM, PROSTAATCARCINOOM EN TESTISCARCINOOM Niet alle studies bij blaas­carcinoom te beoordelen met de PASKWIL-criteria

Voor sommige offlabel-indicaties van oncologische geneesmiddelen is (nog) geen vergoeding geregeld. De NVMO inventariseert deze indicaties om vervolgens in overleg met Zorgverzekeraars Nederland ook voor deze indicaties tot een vergoeding te komen. Internist-oncoloog prof. dr. Ronald de Wit buigt zich over de situatie bij prostaatcarcinoom, blaascarcinoom en testiscarcinoom.

‘Er kan worden gesteld dat buiten studieverband tweedelijns chemotherapie bij blaascarcinoom met middelen als vinflunine, docetaxel en paclitaxel wegens geringe effectiviteit geen plaats heeft’

Referenties

  1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737-46.
  2. James ND, Sydes MR, Clarke NW, et al; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163-77.
  3. James ND, de Bono JS, Speras MR, et al; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338-51.
  4. Fizazi K, Tran N, Fein L, et al; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352-60.
  5. Bellmunt J, de Wit R, Vaughn DJ, et al; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015-26.
  6. Vaughn DJ, Bellmunt J, Fradet Y, et al. Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol 2018;36(16):1579-87.
  7. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet 2016;387(10031):1909-20.
  8. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Checkmate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312-22.
  9. Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatinineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(11):1483-92.
  10. Balar AV, Galsky MD, Rosenberg JE, et al; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67-76.
Beleid

OFFLABEL-INDICATIES BIJ BLAASCARCINOOM, PROSTAATCARCINOOM EN TESTISCARCINOOM Niet alle studies bij blaas­carcinoom te beoordelen met de PASKWIL-criteria

Voor sommige offlabel-indicaties van oncologische geneesmiddelen is (nog) geen vergoeding geregeld. De NVMO inventariseert deze indicaties om vervolgens in overleg met Zorgverzekeraars Nederland ook voor deze indicaties tot een vergoeding te komen. Internist-oncoloog prof. dr. Ronald de Wit buigt zich over de situatie bij prostaatcarcinoom, blaascarcinoom en testiscarcinoom.

‘Er kan worden gesteld dat buiten studieverband tweedelijns chemotherapie bij blaascarcinoom met middelen als vinflunine, docetaxel en paclitaxel wegens geringe effectiviteit geen plaats heeft’

Referenties

  1. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373(8):737-46.
  2. James ND, Sydes MR, Clarke NW, et al; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163-77.
  3. James ND, de Bono JS, Speras MR, et al; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338-51.
  4. Fizazi K, Tran N, Fein L, et al; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352-60.
  5. Bellmunt J, de Wit R, Vaughn DJ, et al; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015-26.
  6. Vaughn DJ, Bellmunt J, Fradet Y, et al. Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol 2018;36(16):1579-87.
  7. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet 2016;387(10031):1909-20.
  8. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Checkmate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312-22.
  9. Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatinineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(11):1483-92.
  10. Balar AV, Galsky MD, Rosenberg JE, et al; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389(10064):67-76.
Over dit artikel
Auteur
Marten Dooper
Over de auteur

Dr. Marten Dooper, wetenschapsjournalist

Printdatum
26 april 2019
E-pubdatum
29 april 2019
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteur
Marten Dooper
Over de auteur

Dr. Marten Dooper, wetenschapsjournalist

Printdatum
26 april 2019
E-pubdatum
29 april 2019
ISSN print
1388-2295
ISSN online
2405-4763